FibroBiologics (NASDAQ:FBLG) Announces Earnings Results

FibroBiologics (NASDAQ:FBLG – Get Free Report) announced its earnings results on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.25, FiscalAI reports.

FibroBiologics Trading Down 2.6%

Shares of FibroBiologics stock traded down $0.02 during trading on Monday, hitting $0.90. 97,460 shares of the stock traded hands, compared to its average volume of 230,361. The firm has a market cap of $6.01 million, a P/E ratio of -0.17 and a beta of 1.81. The stock’s fifty day simple moving average is $1.18 and its 200 day simple moving average is $2.13. FibroBiologics has a 52-week low of $0.62 and a 52-week high of $9.60.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on FBLG. Deutsche Bank lowered FibroBiologics to an “underperform” rating in a research report on Tuesday, August 4th. Weiss Ratings raised shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, September 4th. HC Wainwright restated a “buy” rating and issued a $6.00 price objective (down from $8.00) on shares of FibroBiologics in a report on Tuesday, August 4th. Finally, Wall Street Zen raised FibroBiologics to a “hold” rating in a research report on Saturday, October 10th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $73.00.

View Our Latest Research Report on FBLG

FibroBiologics Company Profile

(Get Free Report)

FibroBiologics is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research centers on fibroblasts, cells found in connective tissue that can support tissue repair and other biological processes. The company is developing potential therapies for conditions including multiple sclerosis, degenerative disc disease, wound healing and diabetes. Its programs are investigational, and the company’s approach includes exploring fibroblast cells and related technologies as treatments.

Read More

Earnings History for FibroBiologics (NASDAQ:FBLG)

Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.